Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Inhibikase Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and the assigned art units. Timothy R Rozof is the busiest examiner with 1 pending action.
This small set of 2 actions is entirely decentralized, with each case being handled by a different examiner. The outcome of the current pending portfolio depends on the individual review of these examiners across their respective technical groups. Practitioners must address the specific requirements of each examiner and art unit independently, as there is no overlap in the current pending workload. This structure ensures that the prosecution of one case does not directly influence the other. The focus remains on these distinct biotechnology and pharmaceutical matters, requiring a tailored strategy for each assigned examiner. The involvement of the art units suggests that the company's innovations are being classified into different specialized categories. This decentralized landscape requires a flexible approach to navigate the unique standards of each department. The outcome of the pending actions will provide a clear indication of the company's standing within these specific technical categories.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| ORWIG, KEVIN S | 1 | 25.5% | +40.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19542047 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION | ROZOF, TIMOTHY R | — |
| 18894338 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | ORWIG, KEVIN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19542047 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION | ROZOF, TIMOTHY R | — |
| 18894338 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | ORWIG, KEVIN S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19542047 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION | ROZOF, TIMOTHY R | 1625 | §102§103 | Final Rejection | — | Pending | Feb 17, 2026 |
| 18894338 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | ORWIG, KEVIN S | 3991 | §102§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInhibikase Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Timothy R Rozof has the most, with 1 of Inhibikase Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
